Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

Syndexa Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on enzyme inhibitors for Alzheimer’s disease and inflammatory diseases, closed a $8.5M Series B financing. Participants include MP Healthcare Venture Management.

Probiodrug (Germany) a clinical-stage biopharmaceutical company focused enzyme inhibitors for Alzheimer’s and inflammatory disease, closed a $20M Series C financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Sciences Partners, Biogen Idec New Ventures, TVM Capital, HBM BioVentures, Goodvent and Wellington Management Company.

Avraham Pharmaceuticals (Israel) a clinical-stage small molecule company focused on the treatment of Alzheimer’s, closed a $3M Series B financing. Participants include Yissum Research Development Foundation, Cial Biotechnology Industries and Technion Research and Development Foundation.

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biotechnology company focused on a protein disaggregation platform for treatment of neurodegenerative diseases, closed a $12.4M Series B financing. Participants include Mérieux Développement and Shire.

Neuroptix (Acton, MA) a clinical-stage diagnostic platform company focused on a non-invasive predictive laser eye assay for the detection and diagnosis of Alzheimer’s, closed a $4M Series C financing. Participants include Inventages Venture Capital.

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

Avraham Pharmaceuticals (Israel) a clinical-stage small molecule company focused on the treatment of Alzheimer’s, closed a $9M Series A financing. Participants include Yissum Research Development Company, Pontifax and Clal Biotechnology Industries.